3.595

1.05% 0.045

Relay Therapeutics Inc (RLAY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RLAY? Forum Prognose

Schlusskurs vom Vortag:

$3.55

Offen:

$3.57

24-Stunden-Volumen:

684.47K

Relative Volume:

0.30

Marktkapitalisierung:

$598.34M

Einnahmen:

$25.55M

Nettoeinkommen (Verlust:

$-341.97M

KGV:

-1.2839

EPS:

-2.8

Netto-Cashflow:

$-304.44M

1W Leistung:

+1.91%

1M Leistung:

+6.76%

6M Leistung:

-25.73%

1J Leistung:

-44.64%

1-Tages-Spanne:

$3.52

$3.635

1-Wochen-Bereich:

$3.49

$3.75

52-Wochen-Spanne:

$1.775

$10.72

Relay Therapeutics Inc Stock (RLAY) Company Profile

Firmenname

Relay Therapeutics Inc

Sektor

Healthcare (1163)

Branche

Biotechnology (657)

Telefon

617-370-8837

Adresse

399 BINNEY STREET, CAMBRIDGE

Mitarbeiter

259

Twitter

Nächster Verdiensttermin

2025-02-21

Neueste SEC-Einreichungen

RLAY's Discussions on Twitter

Vergleichen Sie RLAY mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RLAY Relay Therapeutics Inc	3.595	598.34M	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	466.50	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	548.47	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	319.36	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	538.93	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	243.92	28.51B	3.81B	-644.79M	-669.77M	-6.24

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-17	Eingeleitet	Wells Fargo	Equal Weight
2024-09-10	Fortgesetzt	Goldman	Buy
2024-09-10	Hochstufung	Jefferies	Hold → Buy
2024-09-10	Herabstufung	Oppenheimer	Outperform → Perform
2024-05-10	Hochstufung	Barclays	Equal Weight → Overweight
2023-04-20	Hochstufung	Jefferies	Underperform → Hold
2023-04-19	Hochstufung	Raymond James	Outperform → Strong Buy
2023-04-13	Eingeleitet	Raymond James	Outperform
2023-02-03	Eingeleitet	Oppenheimer	Outperform
2022-09-30	Eingeleitet	Barclays	Equal Weight
2022-09-02	Eingeleitet	Stifel	Buy
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-02-01	Eingeleitet	Berenberg	Buy
2021-07-21	Eingeleitet	BofA Securities	Buy
2020-12-15	Bestätigt	H.C. Wainwright	Buy
2020-12-08	Eingeleitet	JMP Securities	Mkt Outperform
2020-11-05	Eingeleitet	H.C. Wainwright	Buy
2020-08-10	Eingeleitet	Cowen	Outperform
2020-08-10	Eingeleitet	Goldman	Buy
2020-08-10	Eingeleitet	Guggenheim	Buy
2020-08-10	Eingeleitet	JP Morgan	Neutral

Alle ansehen

Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten

Jun 18, 2025

In the Green: Relay Therapeutics Inc (RLAY) Closes at 3.06, Up/Down -6.42 from Previous Day - DWinneX

Jun 18, 2025

Jun 14, 2025

Relay Therapeutics’ SWOT analysis: AI-driven drug discovery stock faces pivotal phase - Investing.com India

Jun 14, 2025

Jun 12, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by California State Teachers Retirement System - Defense World

Jun 12, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News - GuruFocus

Jun 12, 2025

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar to Board of Directors - citybiz

Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com India

Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial By Investing.com - Investing.com South Africa

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar To Board Of Directors - MarketScreener

Jun 11, 2025

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Bluefield Daily Telegraph

Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 9,293 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Jun 11, 2025

Jun 10, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025

Jun 09, 2025